Skip to main content
Equibles
OTLK logo

OTLK · Outlook Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track OTLK — free

Use OTLK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OTLK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.59 +0.02 (+3.13%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 18, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because our cash and cash equivalents, together with $51.1 million of net proceeds from our August 2026 Offering, will not be adequate to fund our currently planned operations through at least the 12 months from the date of this Quarterly Report, there is substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 18, 2026
Market Cap
$155.68M
Shares
243.45M
Volume · Oct 2 5.62M Avg daily vol (3M) 13.63M

Outlook Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Outlook Therapeutics, Inc. (OTLK), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Conference
Investor event
2026-08-14
Outlook Therapeutics, Inc. (OTLK) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-08-14
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
Confident tone European Commercial Challenges and Restructuring Manufacturing and Supply Readiness Market Opportunity and Peak Sales Target
Diluted EPS
$-0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-08-14
Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript
Confident tone NORSE EIGHT clinical trial and US BLA Commercial launch in Europe Inventory and manufacturing
Diluted EPS
$-0.89
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-05-16
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
Confident tone Execution and milestone risk US BLA path and NORSE EIGHT European regulatory approval and launch
Diluted EPS
$-8.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-17
Outlook Therapeutics, Inc. (OTLK) Q4 2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q2
2022-05-13
Outlook Therapeutics, Inc. (OTLK) Q2 2022 Earnings Call
Diluted EPS
$-1.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-02-26
Outlook Therapeutics, Inc. (OTLK) Q1 2022 Earnings Call
Diluted EPS
$-1.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-05-20
Outlook Therapeutics, Inc. (OTLK) Q2 2021 Earnings Call
Diluted EPS
$-1.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-02-19
Outlook Therapeutics, Inc. (OTLK) Q1 2021 Earnings Call
Diluted EPS
$-2.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–9 of 9 webcasts
Key facts CIK 1649989 CUSIP 69012T305 13F (30d) 11 filings 3 filers Visit website Investor relations